The risks of risk aversion in drug regulation.
Drugs are approved by regulatory agencies on the basis of their assessment of whether the available evidence indicates that the benefits of the drug outweigh its risks. In recent years, regulatory agencies have been criticized both for being overly tolerant of risks or being excessively risk-averse, which reflects the challenge in determining an appropriate balance between benefit and risk with the limited data that is typically available before drug approval. The negative consequences of regulatory tolerance in allowing drugs onto the market that turn out to be unsafe are obvious, but the potential for adverse effects on public health owing to the absence of new drugs because of regulatory risk-aversion is less apparent. Here, we discuss the consequences of regulatory risk-aversion for public health and suggest what might be done to best align acceptance of risk and uncertainty by regulators with the interests of public health.
1] European Medicines Agency, 7 Westferry Circus, London E14 4HB, UK. [2].
Hans-Georg
HG
Eichler
Brigitte
B
Bloechl-Daum
Daniel
D
Brasseur
Alasdair
A
Breckenridge
Hubert
H
Leufkens
June
J
Raine
Tomas
T
Salmonson
Christian K
CK
Schneider
Guido
G
Rasi
D000818:Animals; D004335:Drug and Narcotic Control / Q000379:methods*; D006801:Humans; D004364:Pharmaceutical Preparations / Q000592:standards; D018570:Risk Assessment / Q000379:methods
D004364:Pharmaceutical Preparations